InterveXion Therapeutics intervexion.com


Public list: BIO 2016 (619) Pharma Startups (4732) Cancer Therapeutics (1137)

InterveXion Therapeutics is a drug discovery and development company focused on antibody-based therapies for treating human disease. The company are developing monoclonal antibodies to treat substance abuse from PCP and methamphetamine.

InterveXion Therapeutics is a drug discovery and development company focused on antibody-based therapies for treating human disease. The company are developing monoclonal antibodies to treat substance abuse from PCP and methamphetamine.

Company (Alive / Active)

Phone:

Fax:

Little Rock, 72205
Arkansas, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
InterveXion Therapeutics $0M Nov 30, 2018
See all 17 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related InterveXion Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Cognition Therapeutics

Pittsburgh, Pennsylvania, United States
Alive / ActiveCognition Therapeutics is focused on the discovery and development of small molecule therapeutics targeting toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large number of human diseases, and there are currently no therapeutics available to prevent toxic protein accumulation or block their destructive effects. Cognition is founded on the combination of biological expert...Show allLogin to see details

Archemix

San Francisco, California, United States
Alive / ActiveArchemix discovers, develops, and commercializes therapeutic aptamers for the prevention and treatment of chronic and acute diseases. The Company's aptamer product candidates include ARC1779 for thrombotic microangiopathyies and carotid endarterectomy surgical procedure. The company also offers product candidates for cardiovascular, hematology, and oncology diseases.Login to see details
See all 17 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)